Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Regulatory News (SAR)

Share Price Information for Sareum (SAR)

Share Price is delayed by 15 minutes
Get Live Data
22.50    1.00 (4.65%)
Bid:
22.00
Ask:
23.00
Spread: 1.00 (4.545%)
Market Cap: £31.18m
SAR Live PriceLast checked at - London Stock Exchange

Intraday Sareum Share Chart

Corporate update

19 Jun 2008 07:00

RNS Number : 0476X
Sareum Holdings PLC
19 June 2008
 



19 June 2008

SAREUM HOLDINGS PLC

("Sareum" or "the Company")

Corporate Update

Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery business, announced on 2 May 2008, that the Board was undertaking a strategic review to consider how best to take the business forward and create value for shareholders. 

 

On 14 May, the Company announced that as part of the strategic review, the board had implemented a staff restructuring process to reduce its cost base by approximately one third and prepare itself for any potential acquisition or re-financing whilst the future business strategy is under consideration. The restructuring programme has been successfully completed and the Sareum board will continue to review the Company's cost base diligently. In addition, the Company is making progress on a number of fronts and these are described below.

Following announcement of the review on 2 May, Sareum has received expressions of interest in parts or all of its business, particularly its valuable drug discovery programmes, and has received interest in and possible offers to partner, fund, acquire or invest in certain of its programmes or assets. Any transaction resulting from these discussions would lead to an injection of cash into the Company. Initial due diligence is currently being undertaken in respect of several of these discussions. These discussions are at various stages and there is no certainty that any one of them will lead to an offer being made for the Company or any of its assets. The Sareum board continues to actively progress discussions and further announcements will be made as appropriate. 

The Board has concluded, as a result of this review, that the Company should undertake a strategic transaction and it will need to effect a fundraising to enable it to complete such a transaction. In order to facilitate this, the Company will shortly be sending a notice to shareholders convening a general meeting at which shareholders will be asked to give the directors authority to issue further shares for cash. Should the Board decide within a short timescale that strategic transaction is not achievable, the Board will take a decision as to the future of the Company in its present form, as the Company would not be able to continue operations without a significant fundraising.

- Ends-

For further information please contact

Sareum Holdings plc

01223 497700

Tim Mitchell, Chief Executive Officer

 

Buchanan Communications

020 7466 5000

Tim Anderson, Mary-Jane Johnson 

 

Grant Thornton Corporate Finance

020 7383 5100

Philip Secrett, Colin Aaronson

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQVLFFVQBZBBD
Date   Source Headline
2nd Apr 20197:00 amRNSPreclinical Data for SRA737 Presented at AACR 2019
12th Mar 20197:00 amRNSSareum Holdings PLC Issue of Options
4th Mar 20197:00 amRNSHALF-YEARLY RESULTS ENDED 31 DECEMBER 2018
28th Feb 20192:04 pmRNSSierra Oncology has reported its 2018 Results
28th Feb 20198:14 amRNSNew SRA737 preclin data to be presented at AACR
23rd Jan 20191:38 pmRNSSierra Oncology to present SRA737 at DDR Tx Summit
18th Dec 201812:35 pmRNSResults of AGM
18th Dec 20187:00 amRNSAGM Statement
30th Nov 201811:17 amRNSAmendment to Preclinical Efficacy Announcement
30th Nov 20187:45 amRNSPreclinical Efficacy for Immunotherapy Combination
15th Nov 201810:24 amRNSPreclinical Data for SRA737 in Ovarian Cancer
14th Nov 20187:00 amRNSAGM NOTICE
13th Nov 20187:00 amRNSDirectorate Change
8th Nov 201812:28 pmRNSSierra Oncology Q3 2018 Results
26th Oct 20187:00 amRNSCompletion of Placing
1st Oct 20187:00 amRNSFINAL RESULTS FOR THE YEAR ENDED 30 JUNE 2018
27th Sep 20181:03 pmRNSNotice of Results
26th Sep 20187:00 amRNSTYK2/JAK1 selected for certain cancers
11th Sep 20187:00 amRNSPre-Close Trading Statement
10th Sep 20187:00 amRNSSelection of TYK2/JAK1 for autoimmune diseases
9th Aug 20181:15 pmRNSSareum notes Sierra Oncology Q2 2018 Results
11th Jul 20189:38 amRNSNotification of PCA Shareholding
15th Jun 20187:00 amRNSAdvisers
31st May 20187:00 amRNSSareum regains rights to Aurora+FLT3 inhibitors
10th May 201812:21 pmRNSSRA737 trial update in Sierra Oncology Q1 Results
24th Apr 20187:00 amRNSSareum to Present at BioTrinity 2018 in London
17th Apr 201812:45 pmRNSAACR 2018 Update
15th Mar 20187:00 amRNSLate-breaker abstract for SRA737 accepted for AACR
13th Mar 20187:00 amRNSInterim Results
27th Feb 201812:50 pmRNSSierra Oncology expands SRA737 development program
22nd Feb 20187:00 amRNSPreclinical synergy of sra737 and PARP inhibitor
13th Feb 20187:00 amRNSNotice of Interim Results
20th Dec 201711:00 amRNSIssue of Options
19th Dec 20177:00 amRNSPatent Grants in Japan & China for TYK2 Inhibitors
14th Dec 201711:01 amRNSResult of AGM
14th Dec 20177:00 amRNSAGM Statement
20th Nov 20177:00 amRNSNotice of AGM and Annual Report & Accounts
14th Nov 201712:05 pmRNSPlacing
31st Oct 20177:00 amRNSSierra Reports Preclinical Data for Chk1 Inhibitor
19th Oct 20177:00 amRNSFinal Results
9th Oct 201712:00 pmRNSSierra Oncology host KOL Meeting on 12 Oct in NY
18th Sep 201712:00 pmRNSSierra Oncology to host call on Chk1 inhibitor
22nd Aug 20177:00 amRNSPre-Close Trading Statement
19th Jun 20177:00 amRNSSareum to Present at the ICCS 2017
5th Jun 201712:13 pmRNSChk1 Clinical Trials Update
31st May 20177:00 amRNSSierra Oncology Granted US and EU Patents
25th May 20177:00 amRNSSierra Oncology to Present at ASCO Annual Meeting
9th May 20177:00 amRNSSareum to Present at BioTrinity 2017
9th Mar 20177:00 amRNSDirector Shareholding
20th Feb 20177:00 amRNSHalf-year Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.